Akero Therapeutics, Inc.

NASDAQ (USD): Akero Therapeutics, Inc. (AKRO)

Last Price

51.47

Today's Change

-0.24 (0.46%)

Day's Change

49.38 - 57.48

Trading Volume

5,168,032

Overview

Market Cap

3 Billion

Shares Outstanding

69 Million

Avg Volume

729,394

Avg Price (50 Days)

28.75

Avg Price (200 Days)

25.97

PE Ratio

-13.62

EPS

-3.78

Earnings Announcement

26-Feb-2025

Previous Close

51.71

Open

54.46

Day's Range

49.38 - 57.48

Year Range

15.32 - 57.48

Trading Volume

5,194,827

Price Change Highlight

1 Day Change

-0.46%

5 Day Change

107.79%

1 Month Change

82.19%

3 Month Change

73.24%

6 Month Change

83.04%

Ytd Change

83.30%

1 Year Change

118.37%

3 Year Change

211.75%

5 Year Change

117.17%

10 Year Change

180.95%

Max Change

180.95%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment